Human Longevity, Inc. is a

San Diego San Diego ( , ; ) is a city on the Pacific Ocean coast of Southern California located immediately adjacent to the Mexico–United States border. With a 2020 population of 1,386,932, it is the List of United States cities by population, eigh ...

-based venture launched by

Craig Venter John Craig Venter (born October 14, 1946) is an American biotechnologist and businessman. He is known for leading one of the first draft sequences of the human genome and assembled the first team to transfect a cell with a synthetic chromosome. ...

and

Peter Diamandis Peter H. Diamandis (; born May 20, 1961) is a Greek Americans, Greek-American engineer, physician, and entrepreneur best known for being founder and chairman of the X Prize Foundation, cofounder and executive chairman of Singularity University a ...

in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging. The company received in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016. It has made deals with drug companies

Celgene Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated i ...

and

AstraZeneca AstraZeneca plc () is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas includin ...

to collaborate in its research.

Overview

While it is conducting research, the company is offering a wellness service known as "Health Nucleus," which offers customers a range of medical tests such as a full genome sequencing and tests for early indications of

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

Alzheimer's Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As t ...

and

heart disease Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). Other CVDs include stroke, hea ...

. This testing is meant to help people catch diseases earlier than otherwise possible and to identify risk factors for diseases later in life. At the start of 2017, the company hired Cynthia Collins from GE Healthcare, and Venter became Executive Chair. The company's chief operating officer, Mark Winham, left the company in mid-2017, and Collins and the company's chief medical officer, Brad Perkins, left in December. Venter stepped back into the

CEO A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especially ...

role, but announced in May 2018 that he was leaving the company to return to the J. Craig Venter Institute. Venter was sued for allegedly 'stealing trade secrets' at Human Longevity. The case has been dismissed. In November 2019, Human Longevity close
$30 million financing
fro
Emerging Technology Partners (ETP)
and other leading healthcare investors to renew its commitment to longevity and precision health. In November 2019,

C. Thomas Caskey Charles Thomas Caskey (September 12, 1938 – January 13, 2022), also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Huma ...

, MD, FACP, FACMG, FRSC and Professor, Molecular & Human Genetics at the Baylor College of Medicine
joined the company as Chief Medical Officer
In January 2020, Human Longevity published a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS). The study titled, “Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging”, showed that by integrating whole-genome sequencing with advanced imaging and blood metabolites, clinicians identified adults at risk for key health conditions. In June 2020, Human Longevity launched a proprietary program called 100+ longevity program. The program claims to combine the most advanced technologies with a dedicated medical team to help people achieve their healthiest and longest life. See also
How to Live to 100 With Great Quality of Life
In June 2022, Human Longevity announced an

IPO An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investment ...

through SPAC with an evaluation of 1 billion dollars. See also
Human Longevity plans to go public in $1 bln blank-check deal

References

External links

* {{authority control Genetics organizations Human genome projects Biogerontology organizations Life extension organizations Biotechnology companies of the United States 2013 establishments in California